Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity
This article was originally published in RPM Report
Executive Summary
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.
You may also be interested in...
The Consequences of Caronia: Impact On FDA’s Off-Label Regulation
The government has decided not to appeal the Second Circuit’s Caronia off-label promotion ruling – no doubt in part because of concerns about the broad reading of the First Amendment currently in favor at the Supreme Court. Officially, FDA has adopted a low-key response. Unofficially, agency officials – notably Bob Temple – are outraged by the ruling. What does Caronia mean for the future of FDA regulation and off-label prosecutions?
Interpreting a Surprisingly Broad Decision
In striking down a Vermont law that restricted drug companies’ use of physician prescribing data, the Supreme Court delivered a surprisingly broad opinion. That has led some legal experts to speculate that the Court expanded the protections of commercial speech under the Constitution. Are challenges to off-label promotion next?
Data Mining Case Struck Down by Supreme Court; IMS Prepares for Future Battles
When the Supreme Court threw out a Vermont law that prevented pharmaceutical companies from using physician prescribing data for marketing purposes, the unexpectedly broad opinion was cheered by Big Pharma and data miners alike. But IMS Health is already gearing up for the next data mining battle. And this time, the company says, the fight will be about protecting patient privacy.